- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04595630
Diagnostic and Prognostic Value of Cardiac Biomarkers for Early Coronary Bypass Occlusion in Patients Undergoing Coronary Revascularization
September 11, 2023 updated by: University Hospital, Basel, Switzerland
This study is to evaluate the correlation between hs-cTn level as cardiac biomarker for ischemia and early graft occlusion as assessed by CCT in patients undergoing coronary bypass surgery.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
The early diagnosis of the periprocedural myocardial infarction (MI) due to the bypass graft occlusion is an important element, in order to introduce early therapeutic strategies.
Invasive coronary angiography (CA) is the gold standard to evaluate the postoperative myocardial ischemia due to the graft occlusion.
Since this procedure has several important risks, such as thromboembolic events, dissection, bleeding, and contrast dye-induced nephropathy, in daily clinical practice, only patients with strong clinical suspicion of early MI following coronary artery bypass grafting (CABG) undergo this invasive procedure.
There is a clinical need for the development of safe and accurate non-invasive diagnostic approaches to assess the early coronary bypass graft occlusion and to predict the consequent MI.
A new clinical approach for the identification of the early post-procedural graft occlusion in patients undergoing CABG surgery is the high-sensitivity cardiac troponin (hs-cTn) cut-off level.
The peri-operative bypass occlusion will be assessed by a Coronary Computed Tomography (CCT) scan which is a widely available non-invasive approach that permits an accurate evaluation of coronary stenosis.
This study is to evaluate the correlation between hs-cTn level as cardiac biomarker for ischemia and early graft occlusion as assessed by CCT in patients undergoing coronary bypass surgery.
Study Type
Observational
Enrollment (Estimated)
480
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Denis Berdajs, Prof. Dr. med.
- Phone Number: +41 61 328 71 80
- Email: denis.berdajs@usb.ch
Study Locations
-
-
-
Basel, Switzerland, 4031
- Recruiting
- Department for Cardiac Surgery, University Hospital Basel
-
Contact:
- Denis Berdajs, Prof. Dr. med.
- Phone Number: +41 61 328 71 80
- Email: denis.berdajs@usb.ch
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Probability Sample
Study Population
All patients who will undergo isolated coronary bypass surgery at the University Hospital Basel.
Description
Inclusion Criteria:
- patients with isolated coronary bypass surgery
Exclusion Criteria:
- Patients withholding or lacking informed consent
- Patients requiring a concomitant procedure
- Exclusion criteria concerning the CCT scan
- Patients with known allergy to iodine-containing contrast agents
- Renal function impairment (serum creatinine >140 mmol/l; estimated glomerular filtration rate (GFR) <30 ml/min/1.73 m2).
- Pregnancy
- Unstable clinical state or severe heart failure
- Patients with registered MI and registered bypass occlusion in coronary angiogram
- Patients that didn't undergo a CCT prior to discharge
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in hs-cTn level (ng/L)
Time Frame: Day 0 to discharge date (max 10 days)
|
hs-cTn level following CABG to correlate between hs-cTn level as cardiac biomarker for ischemia and early graft occlusion as assessed by CCT
|
Day 0 to discharge date (max 10 days)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
All-cause mortality during hospital stay (death before discharge)
Time Frame: Day 0 to discharge date (max 10 days)
|
All-cause mortality during hospital stay (death before discharge)
|
Day 0 to discharge date (max 10 days)
|
Cardiac-related mortality during hospital stay
Time Frame: Day 0 to discharge date (max 10 days)
|
Cardiac-related mortality during hospital stay
|
Day 0 to discharge date (max 10 days)
|
Myocardial infarction during hospital stay
Time Frame: Day 0 to discharge date (max 10 days)
|
Myocardial infarction during hospital stay
|
Day 0 to discharge date (max 10 days)
|
Surgical or percutaneous coronary re-intervention during hospital stay
Time Frame: Day 0 to discharge date (max 10 days)
|
Surgical or percutaneous coronary re-intervention during hospital stay
|
Day 0 to discharge date (max 10 days)
|
Stroke rate during hospital stay
Time Frame: Day 0 to discharge date (max 10 days)
|
Stroke rate during hospital stay
|
Day 0 to discharge date (max 10 days)
|
Incidence of major adverse cardiac and cerebrovascular events (MACCE) during hospital stay
Time Frame: Day 0 to discharge date (max 10 days)
|
Incidence of major adverse cardiac and cerebrovascular events (MACCE) during hospital stay.
MACCE is defined as a combined event of in-hospital mortality, stroke and myocardial infarction.
|
Day 0 to discharge date (max 10 days)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
All-cause mortality
Time Frame: During one-year follow up
|
All-cause mortality
|
During one-year follow up
|
Cardiac-related mortality
Time Frame: During one-year follow up
|
Cardiac-related mortality
|
During one-year follow up
|
Myocardial infarction
Time Frame: During one-year follow up
|
Myocardial infarction
|
During one-year follow up
|
Stroke
Time Frame: During one-year follow up
|
Stroke
|
During one-year follow up
|
Congestive heart failure requiring hospitalization
Time Frame: During one-year follow up
|
Congestive heart failure requiring hospitalization
|
During one-year follow up
|
Surgical or percutaneous coronary intervention
Time Frame: During one-year follow up
|
Surgical or percutaneous coronary intervention
|
During one-year follow up
|
Incidence of major adverse cardiac and cerebrovascular events (MACCE)
Time Frame: During one-year follow up
|
Incidence of major adverse cardiac and cerebrovascular events (MACCE)
|
During one-year follow up
|
Correlation between intraoperative flow measurements and incidence of early bypass occlusion
Time Frame: Day 0 to discharge date (max 10 days)
|
Correlation between intraoperative flow measurements and incidence of early bypass occlusion
|
Day 0 to discharge date (max 10 days)
|
Changes in ECG (= changes in the ST segment), prone for myocardial ischemia, during in-hospital period
Time Frame: Day 0 to discharge date (max 10 days)
|
Changes in ECG (= changes in the ST segment), prone for myocardial ischemia, during in-hospital period
|
Day 0 to discharge date (max 10 days)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Denis Berdajs, Prof. Dr. med., Department of Cardiac Surgery, University Hospital Basel
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 1, 2021
Primary Completion (Estimated)
November 1, 2026
Study Completion (Estimated)
November 1, 2026
Study Registration Dates
First Submitted
October 6, 2020
First Submitted That Met QC Criteria
October 14, 2020
First Posted (Actual)
October 20, 2020
Study Record Updates
Last Update Posted (Actual)
September 13, 2023
Last Update Submitted That Met QC Criteria
September 11, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2020-02257; ch20Berdajs
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Bypass Graft Occlusion
-
Hamilton Health Sciences CorporationGlaxoSmithKlineUnknownCoronary Bypass Graft Failure/OcclusionCanada
-
Chinese University of Hong KongNot yet recruitingCoronary Artery Disease | Dyslipidemias | Hypercholesterolemia | Hyperlipidemia | Coronary Artery Stenosis | Bypass Graft Stenosis | Bypass Graft Occlusion | Coronary Bypass Graft Stenosis
-
Unity Health TorontoApplied Health Research CentreRecruitingAtherosclerosis | Coronary Artery Bypass Graft Surgery | Vein OcclusionCanada, United States
-
Riphah International UniversityCompleted
-
Loma Linda UniversityEdwards LifesciencesCompletedCoronary Artery Bypass GraftUnited States
-
Montreal Heart InstituteCompletedCoronary Artery Bypass GraftCanada
-
North Texas Veterans Healthcare SystemUnknownCoronary Artery Bypass Graft SurgeryUnited States
-
South Valley UniversityActive, not recruitingCoronary Artery Bypass Graft SurgeryEgypt
-
University of Sao PauloFundação ZerbiniCompletedCoronary Artery Bypass Graft SurgeryBrazil
-
Centre hospitalier de l'Université de Montréal...Centre de Recherche du Centre Hospitalier de l'Université de MontréalUnknownGraft Failure | Complications Due to Coronary Artery Bypass GraftCanada
Clinical Trials on data collection from the hospital records
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingChildhood Malignant Tumors of Lower LimbsFrance
-
Fondazione Don Carlo Gnocchi OnlusFondazione Salvatore Maugeri; Fondazione Poliambulanza Istituto OspedalieroRecruiting
-
University Hospital, Basel, SwitzerlandCompletedValgus Malalignment of the KneeSwitzerland
-
University Hospital, Basel, SwitzerlandCompleted
-
Sunnybrook Health Sciences CentreNot yet recruitingPregnancy Related | Fetal Growth Retardation | Preeclampsia | Cervix; Pregnancy | Placental Insufficiency
-
Fondazione Policlinico Universitario Agostino Gemelli...IRCCS Azienda Ospedaliero-Universitaria di Bologna; Fondazione I.R.C.C.S. Istituto... and other collaboratorsNot yet recruitingCerebrovascular DiseaseItaly
-
University Hospital, Basel, SwitzerlandCompletedDegenerative Lumbar Spine DiseasesSwitzerland
-
Abramson Cancer Center at Penn MedicineActive, not recruitingProspective Follow-up of Outcomes in Patients Receiving Photodynamic Therapy for Neoplastic DiseasesNeoplastic DiseaseUnited States
-
University Hospital, MontpellierNeurogenetic department, CHU Bordeaux; Genetic Department , CHU Montpellier-France and other collaboratorsUnknown
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingCerebral Palsy | Encephalopathy | Traumatic Head Injury | Cerebral MalformationFrance